Dattola, A. et al. 2025. Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy. Dermatology Practical & Conceptual. 15, 2 (Apr. 2025), 4976 . DOI:https://doi.org/10.5826/dpc.1502a4976.